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Objective: The curative potential of various bronchoscopic treatments such 
as Nd:YAG laser, photodynamic therapy, and brachytherapy for the 
treatment of intraluminal tumor has been reported previously. Broncho- 
scopic treatment can be used to treat small intraluminal tumor with 
curative intent, such as in patients with roentgenologically occult squamous 
cell cancer. In a retrospective study, we showed that bronchoscopic 
treatment provided excellent local control with surgical proof of cure in 6 of 
11 patients with intraluminal typical bronchial carcinoid. Methods: In a 
prospective study, 19 patients (8 women and 11 men) with resectable 
intraluminai typical bronchial carcinoid have undergone bronchoscopic 
treatment under general anesthesia. Median age was 44 years (range, 20-74 
years). If tumor persisted after 2 bronchoscopic treatment sessions, surgery 
was performed within 4 months after the treatment. Results: Bronchoscopic 
treatment was able to completely eradicate tumor in 14 of the 19 patients 
(complete response rate 73%, 95% Ch 49%-91%). Median follow-up of these 
patients is 29 months (range, 8-62 months). One patient had severe 
cicatricial stenosis after bronchoscopic treatment, and sleeve lobectomy 
was necessary. No residual carcinoid was found in the resected specimen. In 
the remaining 5 patients, bronchoscopic treatment did not result in a 
complete response and radical surgical resection was performed afterward 
with confirmation of residual carcinoid in the resected specimen. Median 
follow-up of the surgical group is 34 months (range, 12-62 months). 
Conclusions: Current data suggest that bronchoscopic treatment may be an 
effective alternative to surgical resection in a subgroup of patients with 
resectable intraluminal typical bronchial carcinoid. It alleviated the neces- 
sity of surgical resection in 68% (95% CI: 43%-87%) of the patients. 
(J Thorac Cardiovasc Surg 1998;116:402-6) 
M any bronchoscopic techniques are currently available for the treatment of patients with 
tracheobronchial malignant umors. 1'2 In patients 
with roentgenologically occult intraluminal tumor, 
bronchoscopic therapy with curative intent, espe- 
cially photodynamic therapy, may provide an alter- 
native to surgery. 37 
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Surgical resection is the treatment of choice in 
patients with bronchial carcinoid and survival has 
been shown to be excellent. In patients with typical 
bronchial carcinoid, even limited surgery, such as 
bronchoplastic surgery, has become an accepted 
treatment modality. 8-11 Until recently, broncho- 
scopic treatment was considered only in patients 
with contraindications for surgical resection. 12 Pre-- 
operative bronchoscopic treatment enabled better 
assessment of tumor growth and restored airway 
patency to improve the preoperative pulmonary 
condition in patients with obstructive pneumonia. 
We 13 reported previously that bronchoscopic 
treatment resulted in histologically confirmed isap- 
pearance of tumor in patients with intraluminal 
typical bronchial carcinoid who underwent surgery 
after bronchoscopic treatment. Bronchoscopic treat- 
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Table I. Patient characteristics, tumor localization, appearance, size and visibility of distal tumor margin, data 
of treatment, reatment outcome, and follow-up 
Patient No., Visibility of Follow-up 
sex, age (YO Localization Size (cm) distal margin BT CR (rno) 
1, M, 29 LMB-LLL 1 Yes 2 × Nd:YAG Yes 51 
2, M, 61 LB6 1 Yes 1 × BE Yes 29 
3, F, 23 RMB 1.5 Yes 1 × Nd:YAG/IXPDT Yes 62 
4, M, 46 B1 1.5 Yes 1 × Nd:YAG Yes 38 
5, F, 20 LMB-LUL 2 No 2 × BE No 12 
6, M, 65 LMB 0.5 Yes I × BE Yes 21 
7, M, 74 LLL 1 Yes 1 × BE Yes 18 
8, M, 31 LUL-LB4, LB5 1.5 No 2 × BE No 23 
9, M, 48 BI 2 Yes 2 × Nd:YAG Yes 42 
10, M, 38 RUt .  1.5 Yes I × BE Yes 33 
11, M, 62 RUL-RB3 l No 2 × BE No 32 
12, F, 41 BI 1 Yes 1 × BE Yes 29 
13, F, 60 LUL  2 No 2 × BE No 38 
14, F, 25 LUL-LLL 1.5 Yes 1 × BE Yes 25 
15, F, 40 LMB-LUL 2 No 2 × Nd:YAG No 44 
16, M, 34 LLL 0.5 Yes 1 × BE Yes 15 
17, F, 56 LUL-LLL 0.4 Yes 1 × BE Yes 8 
18, F, 47 LMB-LLL 2 Yes 2 × BE Yes 12 
19, M, 42 RLL 1 Yes 1 × BE Yes 22 
LMB, Left main bronchus; LLL, left lower lobe; LB6, left bronchial segment umber 6; RMB, right main bronchus; B/, bronchus intermedius; LUL, left upper 
lobe; RUL, right upper lobe, RLL, right lower lobe; BT, bronchoscopic therapy; ND:YAG, ND:YAG laser; BE, bronchoscopic electrocautery; PDT, 
photodynamic therapy; CR, complete response. 
ment may provide a parenchyma-sparing treatment 
alternative for bronchoplastic surgery. This seems to 
be justified by the excellent survival of patients with 
typical carcinoid after bronchoplastic surgery, the 
low rate of lymph node invasion and metastasis, its 
central localization, its tendency for endobronchial 
polypoid growth, without extraluminal extension, 
and the feasibility of using current bronchoscopic 
treatment techniques to obtain tumor necrosis ex- 
tending several millimeters deep. We therefore con- 
ducted a prospective study of bronchoscopic treat- 
ment, using Nd:YAG laser or bronchoscopic 
electrocautery, in carefully selected patients with 
resectable intraluminal typical bronchial carcinoid, 
with the purpose of complete tumor eradication, as 
an alternative for surgical resection. 
Methods 
Patients were selected from consecutive patients re- 
ferred to our clinic because of intraluminal typical bron- 
chial carcinoid. Inclusion criteria were accessibility of 
tumor for the fiberoptic bronchoscope and high-resolu- 
tion computed tomographic (CT) scans showing no signs 
of bronchial wall infiltration (bronchial wall irregularities, 
bronchial wall thickening, peribronchial tumor invasion), 
or enlarged lymph nodes. Scan technique used for high- 
resolution CT was previously described. 14 Bronchoscopic 
treatment was performed by means of high jet ventilation 
with the patient under general anesthesia. Nd:YAG laser 
and bronchoscopic electrocautery with both the rigid and 
fiberoptic bronchoscopes were used to provide optimal 
management in clearing intraluminal tumor mass. 15 In 
case of bronchoscopic electrocautery, the same technique 
has been used as described previously, lr' Carcinoids were 
documented photographically before and immediately 
after treatment. Follow-up bronchoscopic examination 
was performed to assess response 4 to 6 weeks after 
bronchoscopic treatment. In case tumor persisted after 2 
bronchoscopic treatment sessions, surgical resection was 
performed. 
Oral informed consent was obtained from all subjects. 
Before bronchoscopic treatment, here was always a con- 
sensus about treatment strategy between the surgical 
oncologist and the pulmonologist. This study was ap- 
proved by the scientific and ethical board of our hospital. 
Results 
So far, 19 patients (8 women and 11 men), median 
age 44 years, range 20 to 74 years, have been 
treated. Bronchoscopic findings before broncho- 
scopic treatment with regard to localization, esti- 
mated tumor size, and visibility of distal tumor 
margin are shown in Table I. Technique used and 
result of bronchoscopic treatment are also shown in 
Table I. No complications occurred during broncho- 
scopic treatment, and no significant bleeding oc- 
curred. The use of Nd:YAG laser or bronchoscopic 
electrocautery under general anesthesia provided an 
optimal treatment setting to control hemorrhage. 
Follow-up data including treatment management of
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those not obtaining a complete response despite 2 
bronchoscopic treatment sessions are also shown in 
Table I. 
Bronchoscopic treatment was unable to provide a 
complete response in 5 of the 19 patients and radical 
surgery was performed afterward. In all these pa- 
tients distal tumor margin was invisible for the 
bronchoscopist, in patient 5, radical obectomy was 
feasible, whereas before bronchoscopic treatment a 
pneumonectomy was considered necessary. Thus 
bronchoscopic treatment allowed a less extensive 
surgical resection. Patient 3 underwent sleeve lobec- 
tomy because photodynamic therapy resulted in 
nonselective necrosis and caused complete cicatri- 
cial stenosis of the right main stem bronchus. No 
residual carcinoid was found in the resected speci- 
men. In patient 11, the definite diagnosis after sur- 
gery proved to be atypical carcinoid with positive hilar 
node in contrast to the diagnosis before resection. 
Overall, the complete response rate after bron- 
choscopic treatment was 74% (95% CI: 49%-91%), 
and 68% (95% CI: 43%-87%) of the patients were 
spared surgery. During follow-up, bronchoscopic 
examination was performed at a 3- to 4-month 
interval. Median follow-up of patients after bron- 
choscopic treatment has been 29 months (range, 
8-62 months). Surgical patients had a median fol- 
low-up of 34 months (range, 12-62). These patients 
did not undergo regular bronchoscopic examination 
except once after resection, because surgical reseco 
tion was radical. 
Discussion 
This prospective study was started after our ret- 
rospective data showed that bronchoseopic treat- 
ment may provide complete tumor eradication in a 
subgroup of patients with intraluminal typical bron- 
chial carcinoid. Their carcinoid seemed not to be the 
tip of an iceberg] c'Currently, several bronchoscopic 
treatment alternatives are available for palliation in 
patients with obstructive tracheobronchial malig- 
nant tumors]' 2These techniques have been used to 
completely eradicate intraluminal tumor, and their 
curative potential for multiple, occult cancers and 
carcinoma in situ has been established)" 7, 17, 18 The 
indication and limitation of bronchoscopic therapy 
has been addressed recently. 19 The success rate of 
bronchoscopic treatment with curative intent de- 
pends on the malignant behavior of the tumor. 
Patients with occult cancer 3 mm thick or less and 
with a longitudinal axis of 20 mm or less have been 
shown not to have lymph node metastasis. 2°'zl 
Therefore photodynamic therapy has been pro- 
posed as a "normal tissue-sparing" treatment alter- 
native for surgical resection, partly on the basis of 
the issue of photodynamic therapy selectivity. 5'22 
However, data to support this drug selectivity are 
lacking, and skin photosensitivity remains a prob- 
lem.Z3, 24 Randomized trials comparing the different 
bronchoscopic treatment techniques are not avail- 
able. It is, however, fair to ask whether the tech- 
nique per se is the most important determinant for 
cure. 19 Early stage cancers everal millimeters thick 
require necrosis of several millimeters regardless of 
the technique of choice. 
We presumed that the same may apply for the 
selected patients with intraluminal typical bronchial 
carcinoid in whom the relatively benign nature of 
the disease justified bronchoplastic surgery. Previ- 
ous surgical series have shown that bronchoplastic 
surgery is indeed an acceptable treatment s rategy in 
patients with intraluminal or mural, pedunculated 
or sessile typical carcinoid of limited size. 9-11 
As shown in our present series, tumors were 
intraluminal and never exceeded 2 cm in diameter. 
High-resolution CT scan did not show gross peri- 
bronchial tumor involvement.14 In depth necrosis of 
several millimeters i  sufficient o completely eradi- 
cate these tumors. We used both ND:YAG laser 
and electrocautery to achieve this. In our clinical 
experience no difference was found between these 
techniques with regard to tumor clearance. ~ In- 
traluminal typical bronchial carcinoid localizations 
may be such that surgical bronchoplasty is not 
always feasible, resulting in a relatively wasteful 
parenchymal surgical resection, while the "preserva- 
tion of as much normal ung tissue as possible is one 
of the primary goals of therapy. ''25 Previous series 
also show that parenchyma-sparing resection yields 
excellent survival. 9-11'26 Typical carcinoid behaves 
differently from the atypical variant, with excellent 
survival after complete surgical resection despite the 
presence of metastasis in lymph nodes, s'2v It is 
therefore understandable that patients uitable for 
bronchoplastic surgery might be excellent candi- 
dates for bronchoscopic treatment. Our series shows 
that mural type carcinoid was not necessarily the tip 
of an iceberg and that indeed the findings of high- 
resolution CT arc correlated to complete response. 
We have more ditficulties, however, in treating 
intraluminal typical bronchial carcinoid extending to 
the segmental bronchi, where the distal tumor mar- 
gin was invisible for the bronchoscopist. In patients 
5, 8, 11, 13, and 15, tmnor was located in a segmental 
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bronchus of  the left or right upper  lobe, and the 
distal involvement of carcinoid was diflScult o assess 
during and after bronchoscopic treatment.  In retro-  
spect, it was therefore not surprising that broncho-  
scopic t reatment  did not result in complete tumor  
eradicat ion and that salvage surgery was necessary. 
Therefore it seems that patients with intraluminal  
typical bronchial  carcinoid in whom distal tumor  
margin is less clear are not candidates for broncho-  
scopic treatment.  This is a prob lem similar to treat-  
ment of occult squamous cell lung cancer and shows 
the l imitat ion of bronchoscopic t reatment  in gener- 
al.i-4, 19 It is of interest that in pat ient 8, repeated 
thin-section CT scans revealed an enlarged hilar 
node after the first bronchoscopic t reatment  had 
resolved the atelectasis. Transbronchial  needle aspi- 
ration showed carcinoid cells in the hilar node, and 
the pat ient  underwent  surgical resection. In pat ient 
11, complete  response could not be obtained espite 
repeated bronchoscopic treatment,  and in the re- 
sected specimen atypical carcinoid was found with a 
diseased hilar node. This part icular case is a warning 
that bronchoscopic t reatment as the initial therapy 
for pat ients with resectable intraluminal typical 
bronchial  carcinoid may have a certain risk. How- 
ever, the use of general  anesthesia in combinat ion 
with techniques that provide excellent coagulat ion 
enables the bronchoscopists o collect representa-  
tive biopsy specimens for histologic examination. 
Still, definite histologic classification is sometimes 
possible only after a complete surgical resection. 
In conclusion, bronchoscopic t reatment  seems to 
be an effective initial t reatment alternative for pa- 
tients with resectable intraluminal  typical carcinoid. 
This prospective study supports our earl ier experi- 
ence 13 that pat ients with intraluminal  typical bron- 
chial carcinoid may be given bronchoscopic treat-  
ment after a careful selection has been made. These 
selection criteria are good bronchoscopic tumor  
accessibil ity with clearly visible distal tumor margin 
and high-resolut ion CT scans showing no extralumi- 
nal tumor  extension. Bronchoscopic t reatment  may 
optimize the parenchyma-conserving t reatment  
strategy in patients with intraluminal  typical bron-  
chial carcinoid. 94~ A less extensive surgical resec- 
tion may also be possible after preoperat ive bron- 
choscopic treatment.  Surgery can be per formed 
afterward in case of persistent or residual tumor. 
Longer fol low-up will reveal whether bronchoscopic 
t reatment  is as effective as bronchoplast ic surgery in 
a subgroup of pat ients with resectable intraluminal  
typical bronchial  carcinoid. 
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